The Ehave Inc (OTCPINK: EHVVF) stock closed the Tuesday session almost unchanged at $0.0740, a 0.13% slide. Ehave stock traded from $0.0650 to $0.0821 during Tuesday’s session, and 1.68M shares were traded. In the wake of the appointment of new members to the company’s management team, the EHVVF stock was stable on the day.
What was that new hiring for?
Ehave delivers evidence-based therapeutic interventions to patients through digital therapeutics. The EHVVF emphasizes using digital therapeutics, independently or in conjunction with other therapies and medications, to prevent or treat brain disorders or diseases in order to optimize patient care and health outcomes for patients. Data insights enable clinicians to make objective and intelligent decisions, which is a key product of EHVVF. The Ehave Telemetry Portal is the company’s main product.
Ehave announced the appointment of Jeffrey D. Kamlet as Chief Medical Officer yesterday. EHVVF welcomes Dr. Kamlet to its internal medicine and addiction medicine teams at a time when the organization is growing and implementing the long-range strategy.
EHVVF announced this month that they are offering Ehave medical passports. The passport will give companies the ability to verify their Covid-19 vaccinations as small businesses struggle to figure out how to utilize safety procedures.
Through the EHVVF’s Medical and Vaccine Passport, individuals and small businesses will be able to easily access vaccination verification to enable easy implementation of new safety precautions.
Through a license agreement with Health Wyzz, Ehave (EHVVF) recently expanded the functionality of its Dashboard. EHVVF Dashboard includes a HIPAA-compliant, mobile platform that allows users to manage and retrieve their medical records through a dedicated Amazon Web Services instance.